Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 27:66:55-59.
doi: 10.1016/j.euros.2024.06.004. eCollection 2024 Aug.

RAISN: Robot-assisted Indocyanine Green-guided Sentinel Node Biopsy in Clinical Stage I Germ Cell Tumor

Marieke Sofie Vermeulen-Spohn  1 , Pailin Pongratanakul  1 , Sophia Thy  1 , Juergen Dukart  2 , Peter Albers  1 , Yue Che  1
Affiliations

RAISN: Robot-assisted Indocyanine Green-guided Sentinel Node Biopsy in Clinical Stage I Germ Cell Tumor

Marieke Sofie Vermeulen-Spohn et al. Eur Urol Open Sci. .

Abstract

Robot-assisted imaging-guided sentinel lymph node biopsy is a novel technique that has not been widely investigated in testicular germ cell tumor (GCT). Current staging strategies have poor accuracy for prediction of occult metastatic disease in clinical stage I GCT. Feasibility studies have used 99mTc-nanocolloid staining during laparoscopic procedures. The RAISN trial is investigating robot-assisted lymph node resection guided by indocyanine green fluorescence imaging. This new diagnostic approach is potentially more precise and easier to apply, and is widely available. Confirmation of its utility could change the management of newly diagnosed GCT by reducing overtreatment and treatment-related toxicity.

Keywords: Indocyanine green; Lymph node biopsy; Nodal staging; Occult metastasis; Retroperitoneal lymphadenectomy; Sentinel lymph nodes; Testicular cancer.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Study design.
Fig. 2
Fig. 2
Patient positioning for surgery (right-sided).
Fig. 3
Fig. 3
Sentinel node without fluorescence camera.
See this image and copyright information in PMC

References

    1. Rajpert-De Meyts E., McGlynn K., Okamoto K., Jewett M., Bokemeyer C. Testicular germ cell tumours. Lancet. 2015;387:1762–1774. - PubMed
    1. Groll R.J., Warde P., Jewett M.A.S. A comprehensive systematic review of testicular germ cell tumor surveillance. Crit Rev Oncol Hematol. 2007;64:182–197. - PubMed
    1. Hellesnes R., Myklebust T.Å., Fosså S.D., et al. Testicular cancer in the cisplatin era: causes of death and mortality rates in a population-based cohort. J Clin Oncol. 2021;39:3561–3573. - PubMed
    1. Lubberts S., Groot H., de Wit R., et al. Cardiovascular disease in testicular cancer survivors: identification of risk factors and impact on quality of life. J Clin Oncol. 2023;41:3512–3522. - PMC - PubMed
    1. Chang W., Neal R., Forster M., Lai A. Cumulative burden of 144 conditions, critical care hospitalisation and premature mortality across 26 adult cancers. Nature Commun. 2023;14:1484. - PMC - PubMed

LinkOut - more resources